Keywords: combo, therapy, dupont, merck, sustiva, investigational, non-nucleoside
Combo Therapy With DuPont Merck's Sustiva
Article | 20 October 1997
DuPont Merck's investigational non-nucleoside reverse transcriptaseinhibitor Sustiva (efavirenz or DMP 266) has demonstrated significant viral load reduction in HIV-infected patients receiving ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
